Sexually Transmitted Infections

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

As strains of antibiotic-resistant gonorrhea spread, zoliflodacin provides an alternative oral treatment with non-inferiority to other methods.

The nearly 4000 cases in 2023 were the highest number reported in over 30 years, the Task Force stated.

A novel oral antibiotic, gepotidacin (Blujepa; GSK), has demonstrated its effectiveness in treating uncomplicated urogenital gonorrhea, according to the results of a recent phase 3 clinical trial.

A recent study highlights the genetic diversity within the ompA-genotype L2b clade, improving understanding of sexually transmitted infections and their transmission patterns.

The new panels, leveraging rapid polymerase chain reaction technology, allow point of care sexually transmitted infection diagnosis in 20 minutes, enhancing targeted treatment and reducing follow-up losses.

HPV vaccination in Brazil led to significant reductions in genital warts and cervical precancer hospitalizations, especially among those under 20 years of age.

The over-the-counter, at-home test provides blood results in 15 minutes that could help result in sooner syphilis diagnoses.

Adherence to guideline-based laboratory testing and treatment of chlamydia and gonorrhea in pregnant women has been found to be suboptimal in the United States, indicating the potential for negative effects on newborn and maternal health.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting found an increase of 4 days between diagnosis and treatment among pregnant patients with congenital syphilis vs those without congenital syphilis.

A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting highlights the importance of affordability and convenience in boosting STI test uptake among adolescents and young adults.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Following evidence from recent studies, the Centers for Disease Control and Prevention has recommended the use of doxycycline postexposure prophylaxis in sexual health among certain populations.

A recent study highlights the necessity of optimizing secondary prevention strategies to mitigate adverse cardiovascular outcomes in patients with HIV who face higher risks.

Despite WHO’s goals to reduce syphilis and other STI infections by 2030, rising case numbers underscore the urgent need for intensified global disease prevention and control efforts.

Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.

Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.

Discover the findings from a recent study highlighting the need to enhance vaccination rates among pregnant individuals living with HIV, shedding light on key factors influencing vaccine receipt.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.